The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy

Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research

Carol Kilkenny, William J. Browne, Innes C. Cuthill et al. · PLoS Biology · 2010 · 7.3K citations · Full text

Medicine, Biomedical Sciences, Epidemiology +12

Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research

Carol Kilkenny, William J. Browne, Innes C. Cuthill et al. · Journal of Pharmacology and Pharmacotherapeutics · 2010 · 6.3K citations · Full text

Medicine, Biomedical Sciences, Epidemiology +12

The sodium/glucose cotransport family SLC5

Ernest M. Wright, Eric Turk · Pflügers Archiv - European Journal of Physiology · 2004 · 534 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +6

Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis

Narjes Nasiri‐Ansari, Chrysa Nikolopoulou, Katerina Papoutsi et al. · International Journal of Molecular Sciences · 2021 · 293 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet

Ji Hye Han, Tae Jung Oh, Ghayoung Lee et al. · Diabetologia · 2016 · 281 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17